Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Clinical trial of razoxane and radiotherapy for inoperable carcinoma of the bronchus

Conference · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:5275594
One hundred thirteen patients with inoperable carcinoma of the bronchus were randomly allocated to receive either radiotherapy or radiotherapy plus razoxane. They were stratified according to histology and analyzed according to whether they had oat-cell or non oat-cell carcinomas and whether they tolerated only 1 course (3000 rad) or 2 courses (6000 rad) of radiotherapy. Of the patients who had 2 courses of radiotherapy, only 7% developed leukopenia and the same percentage developed severe esophagitis; but of those who had the combined treatment, 32% developed leukopenia and the same percentage developed severe esophagitis. Although the median survival time was greater in those who received the combined treatment in both one treatment and two treatment groups, neither achieved statistical significance. Sixty-four percent of patients who had two treatments (i.e., 6000 rad plus razoxane) survived 12 months; this compares favorably with most other published clinical trials of inoperable carcinoma of the bronchus.
OSTI ID:
5275594
Conference Information:
Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 5:9
Country of Publication:
United States
Language:
English